InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,428.26
(
-0.65%
)
US TECH 100
18,311.40
(
-1.32%
)
Dow Jones
40,652.93
(
0.28%
)
Brent Oil
78.35
(
-1.01%
)
Bitcoin
65,755.75
(
-1.60%
)
Post# of 43161
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

JPG77

Send PM Follow Ignore
Followers 28
Posts 2529
Boards Moderated 0
Alias Born 05/08/2015

JPG77

Re: ohm20 post# 33061

Thursday, 09/09/2021 8:59:40 AM

Thursday, September 09, 2021 8:59:40 AM

Post# of 43161
The FDA's statement to HGEN says everything we need to know. In its letter, FDA stated that it was unable to conclude that the known and potential benefits of lenzilumab outweigh the known and potential risks of its use as a treatment for COVID-19. HGEN's treatment has known risks that the FDA doesn't like, unlike Leronlimab that has no SAEs.

My comments are just my opinions and should NOT be taken as investment advice.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up